Sequencing and curation strategies for identifying candidate glioblastoma treatments
暂无分享,去创建一个
Ajay K. Royyuru | Vladimir Vacic | Laxmi Parida | Kahn Rhrissorrakrai | Christian Stolte | Anne-Katrin Emde | Bo-Juen Chen | Michael C. Zody | Kanika Arora | Filippo Utro | Vaidehi Jobanputra | Minita Shah | Peter Canoll | Ewa A. Bergmann | Alexis Demopoulos | Nicolas Robine | Kazimierz O. Wrzeszczynski | Phaedra Agius | Dimitris G. Placantonakis | Heather Geiger | Cameron Brennan | Vanessa V. Michelini | John G. Golfinos | V. Jobanputra | V. Vacic | M. Zody | R. Darnell | Anne-Katrin Emde | C. Brennan | P. Agius | P. Canoll | J. Golfinos | K. Wrzeszczynski | Heather Geiger | M. Lamendola-Essel | D. Khaira | E. Dikoglu | N. Robine | K. Arora | J. Bruce | A. Omuro | L. Parida | A. Royyuru | K. Rhrissorrakrai | C. Reeves | C. Stolte | M. Daras | A. Omuro | A. Lassman | C. Grommes | J. Boockvar | J. Posner | E. Diamond | F. Utro | J. M. Vogel | D. Orange | D. Placantonakis | M. Frank | A. Calabro | Sadia Rahman | Bo-Juen Chen | E. Pentsova | Robert B. Darnell | Duyang Kim | Jerome B. Posner | Jeffrey Bruce | Takahiko Koyama | Mayu O. Frank | Vanessa Felice | Esra Dikoglu | Sadia Rahman | Alice Fang | Julia L. Moore Vogel | Catherine Reeves | Depinder Khaira | Anthony Calabro | Duyang Kim | Michelle F. Lamendola-Essel | Cecilia Esteves | John Boockvar | Andrew B. Lassman | Christian Grommes | Mariza Daras | Eli Diamond | Antonio Omuro | Elena Pentsova | Dana E. Orange | Stephen J. Harvey | John Kelly | J. Posner | A. Demopoulos | Takahiko Koyama | Anthony M Calabro | V. Felice | Minita J. Shah | C. Esteves | Alice Fang | J. Kelly
[1] E. Miyaoka,et al. A combination of TERT promoter mutation and MGMT methylation status predicts clinically relevant subgroups of newly diagnosed glioblastomas , 2016, Acta neuropathologica communications.
[2] C. Rudin. Vismodegib , 2012, Clinical Cancer Research.
[3] David T. W. Jones,et al. Signatures of mutational processes in human cancer , 2013, Nature.
[4] B. O'neill,et al. Glioblastoma survival in the United States before and during the temozolomide era , 2012, Journal of Neuro-Oncology.
[5] Satoshi O. Suzuki,et al. Epithelioid glioblastoma arising from pleomorphic xanthoastrocytoma with the BRAF V600E mutation , 2014, Brain Tumor Pathology.
[6] Donavan T. Cheng,et al. Precision medicine at Memorial Sloan Kettering Cancer Center: clinical next-generation sequencing enabling next-generation targeted therapy trials. , 2015, Drug discovery today.
[7] C. Baker,et al. Genome Sequencing of Autism-Affected Families Reveals Disruption of Putative Noncoding Regulatory DNA. , 2016, American journal of human genetics.
[8] Vismodegib , 2019, Reactions Weekly.
[9] Obi L. Griffith,et al. Optimizing cancer genome sequencing and analysis. , 2015, Cell systems.
[10] S. Gabriel,et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. , 2010, Cancer cell.
[11] Ming Yan,et al. Plakophilin-2 Promotes Tumor Development by Enhancing Ligand-Dependent and -Independent Epidermal Growth Factor Receptor Dimerization and Activation , 2014, Molecular and Cellular Biology.
[12] W. Sellers,et al. Identification and Characterization of NVP-BKM120, an Orally Available Pan-Class I PI3-Kinase Inhibitor , 2011, Molecular Cancer Therapeutics.
[13] M. Honavar,et al. The prognostic impact of TERT promoter mutations in glioblastomas is modified by the rs2853669 single nucleotide polymorphism , 2016, International journal of cancer.
[14] V. Jobanputra,et al. Analytical Validation of Clinical Whole-Genome and Transcriptome Sequencing of Patient-Derived Tumors for Reporting Targetable Variants in Cancer , 2018, The Journal of molecular diagnostics : JMD.
[15] AACR Project GENIE: Powering Precision Medicine through an International Consortium. , 2017, Cancer discovery.
[16] Steven J. M. Jones,et al. Molecular Profiling Reveals Biologically Discrete Subsets and Pathways of Progression in Diffuse Glioma , 2016, Cell.
[17] Roland Arnold,et al. Combined hereditary and somatic mutations of replication error repair genes result in rapid onset of ultra-hypermutated cancers , 2015, Nature Genetics.
[18] K. Black,et al. Loss of PTEN Is Not Associated with Poor Survival in Newly Diagnosed Glioblastoma Patients of the Temozolomide Era , 2012, PloS one.
[19] C. James,et al. PTEN mutation, EGFR amplification, and outcome in patients with anaplastic astrocytoma and glioblastoma multiforme. , 2001, Journal of the National Cancer Institute.
[20] Laxmi Parida,et al. Watson for Genomics: Moving Personalized Medicine Forward. , 2016, Trends in cancer.
[21] R. Salgia,et al. PI3 Kinase Pathway and MET Inhibition is Efficacious in Malignant Pleural Mesothelioma , 2016, Scientific Reports.
[22] N. McGranahan,et al. Biological and therapeutic impact of intratumor heterogeneity in cancer evolution. , 2015, Cancer cell.
[23] A. Bardelli,et al. MET-Driven Resistance to Dual EGFR and BRAF Blockade May Be Overcome by Switching from EGFR to MET Inhibition in BRAF-Mutated Colorectal Cancer. , 2016, Cancer discovery.
[24] Laxmi Parida,et al. Enhancing Next‐Generation Sequencing‐Guided Cancer Care Through Cognitive Computing , 2017, The oncologist.
[25] Stephen Yip,et al. MSH6 Mutations Arise in Glioblastomas during Temozolomide Therapy and Mediate Temozolomide Resistance , 2009, Clinical Cancer Research.
[26] Lei Shang,et al. Whole-genome sequencing is more powerful than whole-exome sequencing for detecting exome variants , 2014, Proceedings of the National Academy of Sciences.
[27] Edward F. Chang,et al. Tumor Evolution of Glioma-Intrinsic Gene Expression Subtypes Associates with Immunological Changes in the Microenvironment. , 2017, Cancer cell.
[28] Clare Verrill,et al. Clinical whole-genome sequencing from routine formalin-fixed, paraffin-embedded specimens: pilot study for the 100,000 Genomes Project , 2018, Genetics in Medicine.
[29] Bert Vogelstein,et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. , 2015, The New England journal of medicine.
[30] D. Reardon,et al. Programmed death ligand 1 (PD-L1) as an immunotherapy target in patients with glioblastoma. , 2015, Neuro-oncology.
[31] Tracy T Batchelor,et al. A hypermutation phenotype and somatic MSH6 mutations in recurrent human malignant gliomas after alkylator chemotherapy. , 2006, Cancer research.
[32] R. Bernards,et al. Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma , 2014, Nature.
[33] T. Cloughesy,et al. Preliminary safety and activity of nivolumab and its combination with ipilimumab in recurrent glioblastoma (GBM): CHECKMATE-143. , 2015 .
[34] Funded Statistical Methods groups-AWG,et al. Improving genetic diagnosis in Mendelian disease with transcriptome sequencing , 2017 .
[35] Yonghong Xiao,et al. Pattern of retinoblastoma pathway inactivation dictates response to CDK4/6 inhibition in GBM , 2010, Proceedings of the National Academy of Sciences.
[36] V. Vacic,et al. Detection of a Recurrent DNAJB1-PRKACA Chimeric Transcript in Fibrolamellar Hepatocellular Carcinoma , 2014, Science.
[37] P. Park,et al. Copy number analysis of whole-genome data using BIC-seq2 and its application to detection of cancer susceptibility variants , 2016, Nucleic acids research.
[38] O. Kallioniemi,et al. FusionCatcher – a tool for finding somatic fusion genes in paired-end RNA-sequencing data , 2014, bioRxiv.
[39] P. A. Futreal,et al. Loss of the Mismatch Repair Protein MSH6 in Human Glioblastomas Is Associated with Tumor Progression during Temozolomide Treatment , 2007, Clinical Cancer Research.
[40] Francesco Muntoni,et al. Improving genetic diagnosis in Mendelian disease with transcriptome sequencing , 2016, Science Translational Medicine.
[41] Timothy C Ryken,et al. Toward precision medicine in glioblastoma: the promise and the challenges. , 2015, Neuro-oncology.
[42] Donavan T. Cheng,et al. Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT): A Hybridization Capture-Based Next-Generation Sequencing Clinical Assay for Solid Tumor Molecular Oncology. , 2015, The Journal of molecular diagnostics : JMD.
[43] A. Ghazalpour,et al. Multi-platform molecular profiling of a large cohort of glioblastomas reveals potential therapeutic strategies , 2016, Oncotarget.
[44] W. Figg,et al. Precision Oncology Medicine: The Clinical Relevance of Patient‐Specific Biomarkers Used to Optimize Cancer Treatment , 2016, Journal of clinical pharmacology.
[45] In-Hee Lee,et al. Clonal evolution of glioblastoma under therapy , 2016, Nature Genetics.
[46] Miguel Melo,et al. Frequency of TERT promoter mutations in human cancers , 2013, Nature Communications.
[47] S. Baker,et al. PTEN and the PI3-kinase pathway in cancer. , 2009, Annual review of pathology.
[48] K. McDonald,et al. CDK4/6 Inhibitor PD0332991 in Glioblastoma Treatment: Does It Have a Future? , 2015, Front. Oncol..
[49] Thomas Ragg,et al. The RIN: an RNA integrity number for assigning integrity values to RNA measurements , 2006, BMC Molecular Biology.
[50] Steven J. M. Jones,et al. Mutational Analysis Reveals the Origin and Therapy-Driven Evolution of Recurrent Glioma , 2014, Science.
[51] Eric T. Wang,et al. Alternative Isoform Regulation in Human Tissue Transcriptomes , 2008, Nature.
[52] M. Prados,et al. Targeting glioma-initiating cells in GBM: ABTC-0904, a randomized phase 0/II study targeting the Sonic Hedgehog-signaling pathway. , 2014 .
[53] Xin Zheng,et al. Role of the Hedgehog pathway in hepatocellular carcinoma (review). , 2013, Oncology reports.
[54] K. Flaherty,et al. Phase 1 and pharmacodynamic trial of everolimus in combination with cetuximab in patients with advanced cancer , 2014, Cancer.
[55] Theresa Zhang,et al. Personalized genomic analyses for cancer mutation discovery and interpretation , 2015, Science Translational Medicine.
[56] V. Jobanputra,et al. Whole Genome Sequencing-Based Discovery of Structural Variants in Glioblastoma. , 2018, Methods in molecular biology.
[57] R. Elashoff,et al. Human TERT promoter mutation enables survival advantage from MGMT promoter methylation in IDH1 wild-type primary glioblastoma treated by standard chemoradiotherapy , 2016, Neuro-oncology.
[58] Ajay K. Royyuru,et al. Comparing sequencing assays and human-machine analyses in actionable genomics for glioblastoma , 2017, Neurology: Genetics.
[59] Thomas Zichner,et al. DELLY: structural variant discovery by integrated paired-end and split-read analysis , 2012, Bioinform..
[60] M. McMahon,et al. PI3'-kinase inhibition forestalls the onset of MEK1/2 inhibitor resistance in BRAF-mutated melanoma. , 2015, Cancer discovery.
[61] S. Chakradhar. Tumor sequencing takes off, but insurance reimbursement lags , 2014, Nature Medicine.
[62] Donavan T. Cheng,et al. Mutational Landscape of Metastatic Cancer Revealed from Prospective Clinical Sequencing of 10,000 Patients , 2017, Nature Medicine.
[63] J. Bruce,et al. Somatic mutations of PTEN in glioblastoma multiforme. , 1997, Cancer research.
[64] T. Golub,et al. Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion , 2012, Nature.